Josh Schimmer
Stock Analyst at Evercore ISI Group
(3.36)
# 984
Out of 4,876 analysts
130
Total ratings
44.83%
Success rate
3.79%
Average return
Main Sectors:
Stocks Rated by Josh Schimmer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMPS COMPASS Pathways | Downgrades: In-Line | $11 → $6 | $2.77 | +116.61% | 2 | Jun 23, 2025 | |
| SEPN Septerna | Maintains: Overweight | $20 → $25 | $10.51 | +137.87% | 3 | May 16, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Overweight | $20 → $30 | $2.53 | +1,085.77% | 5 | May 16, 2025 | |
| ASND Ascendis Pharma | Maintains: Outperform | $260 → $280 | $172.14 | +62.66% | 4 | May 2, 2025 | |
| CGON CG Oncology | Reiterates: Overweight | $75 | $25.95 | +189.02% | 4 | Apr 28, 2025 | |
| AARD Aardvark Therapeutics | Reiterates: Overweight | $50 | $13.39 | +273.41% | 2 | Apr 1, 2025 | |
| ARTV Artiva Biotherapeutics | Maintains: Overweight | $23 → $20 | $1.47 | +1,260.54% | 2 | Mar 25, 2025 | |
| BBIO BridgeBio Pharma | Reiterates: Overweight | $95 | $44.86 | +111.77% | 11 | Feb 21, 2025 | |
| KRYS Krystal Biotech | Reiterates: Overweight | $215 | $138.88 | +54.81% | 5 | Feb 20, 2025 | |
| SPRO Spero Therapeutics | Downgrades: In-Line | $5 | $2.94 | +70.07% | 4 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $200 | $23.15 | +763.93% | 6 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $16.54 | +51.15% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.05 | - | 5 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $30 | $18.20 | +64.84% | 4 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.84 | - | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.48 | - | 2 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $90 | $29.96 | +200.40% | 6 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $5.49 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $99.49 | - | 5 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $16.08 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $13.33 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.41 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $65.35 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 | $0.34 | +4,260.47% | 3 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $53 | $29.03 | +82.57% | 5 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $32.40 | +100.62% | 3 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $60 | $51.07 | +17.49% | 5 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $1.57 | +3,084.71% | 1 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $43 → $5 | $2.34 | +113.68% | 2 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $11 | $1.31 | +739.69% | 2 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $140 → $130 | $125.42 | +3.65% | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $760 | $521.00 | +45.87% | 2 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $12.47 | +20.29% | 1 | Mar 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $55 | $7.76 | +608.76% | 1 | Feb 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $2.45 | +1,124.49% | 1 | Dec 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $1.01 | - | 4 | Dec 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $8.39 | - | 3 | Feb 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $222 → $250 | $300.75 | -16.87% | 4 | Nov 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $68.37 | - | 2 | Jun 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $39.80 | - | 2 | May 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $2.96 | - | 2 | Mar 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $14.10 | - | 2 | Mar 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $13.86 | +58.73% | 1 | Nov 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $11.22 | - | 2 | Aug 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $55.17 | - | 1 | Aug 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $95 | $182.31 | -47.89% | 1 | Aug 17, 2017 |
COMPASS Pathways
Jun 23, 2025
Downgrades: In-Line
Price Target: $11 → $6
Current: $2.77
Upside: +116.61%
Septerna
May 16, 2025
Maintains: Overweight
Price Target: $20 → $25
Current: $10.51
Upside: +137.87%
Rocket Pharmaceuticals
May 16, 2025
Maintains: Overweight
Price Target: $20 → $30
Current: $2.53
Upside: +1,085.77%
Ascendis Pharma
May 2, 2025
Maintains: Outperform
Price Target: $260 → $280
Current: $172.14
Upside: +62.66%
CG Oncology
Apr 28, 2025
Reiterates: Overweight
Price Target: $75
Current: $25.95
Upside: +189.02%
Aardvark Therapeutics
Apr 1, 2025
Reiterates: Overweight
Price Target: $50
Current: $13.39
Upside: +273.41%
Artiva Biotherapeutics
Mar 25, 2025
Maintains: Overweight
Price Target: $23 → $20
Current: $1.47
Upside: +1,260.54%
BridgeBio Pharma
Feb 21, 2025
Reiterates: Overweight
Price Target: $95
Current: $44.86
Upside: +111.77%
Krystal Biotech
Feb 20, 2025
Reiterates: Overweight
Price Target: $215
Current: $138.88
Upside: +54.81%
Spero Therapeutics
Dec 20, 2024
Downgrades: In-Line
Price Target: $5
Current: $2.94
Upside: +70.07%
Dec 11, 2024
Reiterates: Overweight
Price Target: $200
Current: $23.15
Upside: +763.93%
Dec 11, 2024
Reiterates: Overweight
Price Target: $25
Current: $16.54
Upside: +51.15%
Dec 11, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.05
Upside: -
Oct 8, 2024
Reiterates: Overweight
Price Target: $30
Current: $18.20
Upside: +64.84%
Sep 23, 2024
Downgrades: Neutral
Price Target: n/a
Current: $3.84
Upside: -
Sep 17, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.48
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $90
Current: $29.96
Upside: +200.40%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $5.49
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $99.49
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $16.08
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $13.33
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.41
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $65.35
Upside: -
Aug 26, 2024
Maintains: Outperform
Price Target: $15
Current: $0.34
Upside: +4,260.47%
Aug 26, 2024
Maintains: Outperform
Price Target: $54 → $53
Current: $29.03
Upside: +82.57%
Aug 9, 2024
Reiterates: Overweight
Price Target: $65
Current: $32.40
Upside: +100.62%
Aug 8, 2024
Maintains: Overweight
Price Target: $50 → $60
Current: $51.07
Upside: +17.49%
Jun 21, 2024
Reiterates: Overweight
Price Target: $50
Current: $1.57
Upside: +3,084.71%
Nov 10, 2023
Downgrades: In-Line
Price Target: $43 → $5
Current: $2.34
Upside: +113.68%
Jun 6, 2023
Maintains: Outperform
Price Target: $20 → $11
Current: $1.31
Upside: +739.69%
Nov 14, 2022
Downgrades: In-Line
Price Target: $140 → $130
Current: $125.42
Upside: +3.65%
Oct 17, 2022
Downgrades: In-Line
Price Target: $760
Current: $521.00
Upside: +45.87%
Mar 15, 2022
Initiates: Outperform
Price Target: $15
Current: $12.47
Upside: +20.29%
Feb 2, 2021
Initiates: Outperform
Price Target: $55
Current: $7.76
Upside: +608.76%
Dec 29, 2020
Initiates: Outperform
Price Target: $30
Current: $2.45
Upside: +1,124.49%
Dec 9, 2019
Downgrades: In-Line
Price Target: n/a
Current: $1.01
Upside: -
Feb 25, 2019
Upgrades: Outperform
Price Target: n/a
Current: $8.39
Upside: -
Nov 16, 2018
Upgrades: Outperform
Price Target: $222 → $250
Current: $300.75
Upside: -16.87%
Jun 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $68.37
Upside: -
May 8, 2018
Downgrades: In-Line
Price Target: n/a
Current: $39.80
Upside: -
Mar 12, 2018
Downgrades: In-Line
Price Target: n/a
Current: $2.96
Upside: -
Mar 12, 2018
Downgrades: In-Line
Price Target: n/a
Current: $14.10
Upside: -
Nov 7, 2017
Initiates: Outperform
Price Target: $22
Current: $13.86
Upside: +58.73%
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $11.22
Upside: -
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $55.17
Upside: -
Aug 17, 2017
Initiates: Outperform
Price Target: $95
Current: $182.31
Upside: -47.89%